A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.
By H. Keys, J. Roberts, V. Brunetto, R. Zaino, N. Spirtos, J. Bloss, A. Pearlman, M. Maiman, J. Bell. Gynecologic Oncology, 2004
720 citations recorded by the source corpus.
Subfields: Obstetrics and Gynecology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/c0fcf96226cb1048c60972329a6fc06a1614c502
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Obstetrics and Gynecology
- N. Colombo
- Jonathan A. Ledermann
- Remi A. Nout
- F. Amant
- C. Sessa
- D. Querleu
- Carien L. Creutzberg
- M. Mirza
In Reproductive Medicine
- N. Colombo
- Jonathan A. Ledermann
- Remi A. Nout
- F. Amant
- C. Sessa
- D. Querleu
- Carien L. Creutzberg
- M. Mirza
Citations in the corpus
- Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. (2009, methodology): “Postoperative treatment recommendations, including radiation and/or chemotherapy, are tailored to histologic cell type, nuclear and cytologic grade, depth of myometrial and cervical invasion, lymphovascular space invasion, peritoneal cytology, and stage of disease, with an effort to avoid the toxici”
- A clinically applicable molecular-based classification for endometrial cancers (2015, background): “…staging pathologic examination (principally histotype, tumour grade and stage) that may help guide treatment(s) (Creutzberg et al, 2000; Fanning, 2001; Keys et al, 2004; Mariani et al, 2008; Kwon et al, 2009; Colombo et al, 2013; AlHilli et al, 2014; Bendifallah et al, 2015; Kong et al, 2015).”
- Post operative radiation therapy in endometrial carcinoma : reducing overtreatment and improving quality of life (2013, background): “20 Both PORTEC-1 and GOG#99 trials established risk factors to better select patients at risk of recurrence within the intermediate risk group.(50,51) Using these risk factors (age, grade, depth of myometrial invasion and lymph vascular space invasion), in both trials devised a so-called high-interm”
- ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015, result): “In contrast to the PORTEC-1 trial [117], surgical staging lymphadenectomy was mandatory in the GOG99 trial [118], showing that for node-negative disease, EBRT still reduced the risk of recurrence.”